As of Feb. 26, 2026, two stocks in the consumer discretionary sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, acc ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

AptarGroup (NYSE:ATR) 2026 Conference February 25, 2026 09:45 AM ET Company ParticipantsGeorge Staphos - Managing DirectorMary Skafidas - Head of Investor RelationsStephan Tanda - President and CEOGeorge StaphosStephan Tanda, CEO for the company, and Mary Skafidas, who does a wonderful job on Investor Relations. Here for Aptar, they unfortunately ran the gauntlet and ultimately could not be here live, but we are grateful that they're here virtually. That, you know, all the great work that our conference pla ...

As of Feb. 25, 2026, two stocks in the utilities sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Ben ...

As of Feb. 24, 2026, two stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.Here's the latest list of major overbought players in this sector.Veris Residential Inc (NYSE:VRE)Kennedy-Wilson Holdings Inc (NYSE:KW)Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.Photo via Shutterstock ...

As of Feb. 23, 2026, three stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.Here's the latest list of major overbought players in this sector.Stepan Co (NYSE:SCL)Koppers Holdings Inc. (NYSE:KOP)On Feb. 11, Koppers raised its quarterly dividend from 8 cents to 9 cents per share. The company's stock gained around 21% over the past month and has a 52-week high of $35.70.RSI Value: 81.2KOP Price Action: Shares of Koppers ...

Aristotle Capital Boston, LLC, an investment advisor, released its fourth-quarter investor letter for “Small Cap Equity Fund”. A copy of the letter can be downloaded here. U.S. small-cap equities reported modest gains in the fourth quarter of 2025. The quarter started as a continuation of the post-Liberation Day risk-on market environment, while it ended on a strong note, driven by a positive macroeconomic backdrop. Attractive valuations, earnings recovery, broadening of the market, and a shift from mega-ca ...

Core Insights - AptarGroup's international revenue performance is crucial for assessing its financial resilience and growth prospects [1][2] Group 1: International Revenue Performance - The total revenue for AptarGroup in the recent quarter reached $962.74 million, reflecting a 13.5% increase from the prior-year quarter [4] - Latin America contributed $72.62 million, accounting for 7.5% of total revenue, which was a surprise of +5.5% compared to analysts' expectations [5] - Europe generated $482.12 million, representing 50.1% of total revenue, with a surprise of +9.98% over expected figures [6] - Asia's revenue was $125.64 million, making up 13.1% of total revenue, and exceeded expectations by +18.31% [7] Group 2: Future Revenue Projections - Analysts project AptarGroup's total revenue for the current fiscal quarter to be $948.53 million, indicating a 6.9% increase from the prior-year quarter [8] - For the full year, total revenue is expected to reach $3.86 billion, reflecting a 2.1% increase from the previous year [9] Group 3: Market Context and Stock Performance - The reliance on global markets presents both opportunities and challenges for AptarGroup, making the analysis of international revenue trends essential for future forecasts [10] - Over the past four weeks, AptarGroup's stock has appreciated by 10.7%, while the Zacks S&P 500 composite remained unchanged [13] - In the last three months, the company's shares increased by 16%, outperforming the S&P 500's 3.7% increase [13]

Core Sales Performance - Pharma core sales increased by 4% in the quarter, with prescription core sales growing by 1%, driven by systemic nasal drug delivery and higher royalty payments, despite a 36% decline in emergency medicine sales [1][5][19] - For the quarter ended December 31, 2025, Aptar reported sales of $963 million, a 14% increase from $848 million a year earlier, with core sales reflecting healthy underlying demand across all segments [4][5] Profitability and Financial Metrics - Adjusted EPS for the quarter was $1.25, down from $1.62 in the prior year, attributed to higher depreciation, amortization, and interest expenses [2] - Adjusted EBITDA was $191 million, a 2% decrease year-over-year, with an adjusted EBITDA margin of 19.8%, down from 23% in the prior-year quarter, impacted by unfavorable product mix and higher production costs [3][7] Segment Performance - Injectables core sales increased by 24%, driven by demand for elastomeric components, while consumer healthcare core sales rose by 3% [10] - Beauty segment achieved 10% core sales growth, with personal care growing by 17%, although the adjusted EBITDA margin decreased to 10.2% due to lower-margin projects and operational disruptions [9][12] Capital Allocation and Shareholder Returns - In 2025, the company returned $486 million to shareholders through dividends and share repurchases, with a new $600 million buyback authorization announced [15][16] - Free cash flow was reported at $303 million, down $64 million year-over-year, primarily due to timing of tax payments and higher working capital [14] Outlook and Challenges - For Q1 2026, adjusted EPS is guided to be between $1.13 and $1.21, reflecting higher interest expenses and an expected effective tax rate of 21% to 23% [18] - Management anticipates a $65 million revenue headwind in 2026 due to declining emergency medicine demand, with the impact expected to be more pronounced in the first half of the year [19][20]